Latest Crizotinib Stories
- Marks first commercial oncology milestone for EMD Serono through the global strategic alliance between Merck KGaA, Darmstadt, Germany and Pfizer ROCKLAND, Mass., May 6, 2015 /PRNewswire/
A study published in The Oncologist on February 26, 2015, challenges the role of fluorescence in situ hybridization (FISH) testing as the current gold standard for detecting EML4-ALK rearrangements
The Oncology Institute of Hope and Innovation announces first clinical trial of the year. Downey, CA (PRWEB) January 10, 2015 The Oncology Institute
-- CHOP and Penn Medicine Experts Define Riskier Mutations in Neuroblastoma, Setting Stage for Clinical Trial-- PHILADELPHIA, Nov.
The anti-cancer drug Xalkori® is being investigated by the ECOG-ACRIN Cancer Research Group in E4512, a phase III trial. Philadelphia, PA (PRWEB) August
LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
A University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) draws a line from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation.
- Ceritinib achieved overall response rate of 58.5%, with a median progression-free survival of 8.2 months1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today announced data showing
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).